www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/9763

Title: Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD)
Authors: GEUSENS, Piet
Issue Date: 2009
Publisher: INFORMA HEALTHCARE
Citation: EXPERT OPINION ON BIOLOGICAL THERAPY, 9(5). p. 649-657
Abstract: Background: COX-inhibiting nitric oxide donators (CINODs) are a new class of drugs that combine the actions of the parent COX inhibitor with nitric oxide (NO), with the aim of reducing potential toxicity of the parent drug, while maintaining its analgesic and anti-inflammatory effects. AZD3582 (Naproxcinod (R)) is the first in the class of CINODs. Objective/methods: To review the effects of NO donation, CINODS in general and naproxen in osteoarthritis (OA), based on literature in PubMed. Results: in preclinical and human studies, this drug produced similar analgesic and anti-inflammatory effects to its parent naproxen, with improved gastrointestinal safety in OA patients. The results of recent clinical trials, which were designed to study effects on blood pressure, are expected shortly, after peer-review. Conclusions: As naproxen is considered the safest COX inhibitor choice from a cardiovascular perspective, AZD3582 has the potential to become a new drug treatment in patients with OA, in whom pain and function are not controlled by the use of analgesics.
Notes: [Geusens, Piet] Univ Hasselt, Biomed Res Inst, Maastricht, Belgium.
URI: http://hdl.handle.net/1942/9763
DOI: 10.1517/14712590902926071
ISI #: 000266227700010
ISSN: 1471-2598
Category: A1
Type: Journal Contribution
Validation: ecoom, 2010
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.